Temporalmente, el archivo digital asociado a esta publicación, no se encuentra disponible. Para más información escribir a [email protected]
Este documento se encuentra disponible en su fuente de origen, si desea acceder al texto completo, puedes hacerlo a continuación:
Autor(es)
Simón, Layla; Sanhueza, Sofía; Gaete-Ramírez, Belén; Varas-Godoy, Manuel; Quest, Andrew F.G. |
ISSN:
2234-943X |
Idioma:
eng |
Fecha:
2022-05-11 |
Tipo:
Artículo de revisión |
Revista:
Frontiers in Oncology |
Datos de la publicación:
vol. 12 Issue: Pages: |
DOI:
10.3389/fonc.2022.897205 |
Descripción:
Publisher Copyright: Copyright © 2022 Simón, Sanhueza, Gaete-Ramírez, Varas-Godoy and Quest. |
Resumen:
Advances in our understanding of cancer biology have contributed to generating different treatments to improve the survival of cancer patients. However, although initially most of the therapies are effective, relapse and recurrence occur in a large percentage of these cases after the treatment, and patients then die subsequently due to the development of therapy resistance in residual cancer cells. A large spectrum of molecular and cellular mechanisms have been identified as important contributors to therapy resistance, and more recently the inflammatory tumor microenvironment (TME) has been ascribed an important function as a source of signals generated by the TME that modulate cellular processes in the tumor cells, such as to favor the acquisition of therapy resistance. Currently, extracellular vesicles (EVs) are considered one of the main means of communication between cells of the TME and have emerged as crucial modulators of cancer drug resistance. Important in this context is, also, the inflammatory TME that can be caused by several conditions, including hypoxia and following chemotherapy, among others. These inflammatory conditions modulate the release and composition of EVs within the TME, which in turn alters the responses of the tumor cells to cancer therapies. The TME has been ascribed an important function as a source of signals that modulate cellular processes in the tumor cells, such as to favor the acquisition of therapy resistance. Although generally the main cellular components considered to participate in generating a pro-inflammatory TME are from the immune system (for instance, macrophages), more recently other types of cells of the TME have also been shown to participate in this process, including adipocytes, cancer-associated fibroblasts, endothelial cells, cancer stem cells, as well as the tumor cells. In this review, we focus on summarizing available information relating to the impact of a pro-inflammatory tumor microenvironment on the release of EVs derived from both cancer cells and cells of the TME, and how these EVs contribute to resistance to cancer therapies. |
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |
El Repositorio Institucional de la Universidad San Sebastián reúne los trabajos académicos y de investigación elaborados por la comunidad universitaria. Contribuye a la visibilidad y difusión, para ser consultados a través de acceso abierto por toda la comunidad nacional e internacional.
El objetivo del Repositorio es almacenar, conservar y entregar en formato electrónico, los resultados del quehacer institucional, permitiendo mayor visibilidad y difusión por medio del acceso abierto y gratuito.